Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up Authors: Huan Tao, Nenggang Jiang, Yongqian Jia Published: 2026 ABSTRACT AbstractSecondary pure red cell aplasia (PRCA) is one of the most common cytopenic complications in T-cell large granular lymphocyte (T-LGL) leukemia and requires therapeutic intervention. Refractory T-LGL-associated PRCA lacks a unified salvage regimen, and effective targeted agents remain scarce. In recent years, epigenetic modifications have been implicated in the pathogenesis of T-LGL leukemia, yet relevant clinical evidence is limited. We report a case of refractory T-LGL leukemia complicated by PRCA that was resistant to cyclosporine (CsA). Then the patient achieved rapid disease control with chidamide plus thalidomide in the early phase, and has maintained long-term remission for six years on chidamide monotherapy after thalidomide discontinuation. Notably, clonal T-cell receptor (TCR) variable β-chain (Vβ) 3 persisted on flow cytometry throughout the treatment course. As an epigenetic modulator, chidamide represents a more convenient and promising therapeutic strategy for managing T-LGL leukemia, prompting us to present this case.Keywords: Large granular lymphocyte leukemia, Anemia, Thalidomide, Chidamide, Case report List of abbreviations pure red cell aplasia; T-cell-type large granular lymphocyte; cyclosporine A; Histone deacetylase. Introduction T-cell large granular lymphocyte (T-LGL) leukemia is an indolent lymphoproliferative disorder characterized by the clonal proliferation of CD3+ cytotoxic T cells [1]. >50% of patients present with cytopenia and an increased number of large granular lymphocytes (LGLs) in the peripheral blood, which substantially impair prognosis and survival [2]. Currently, no standardized first-line therapeutic strategy or guideline is available, and most patients are managed empirically with immunosuppressive agents [3]. Secondary pure red cell aplasia (PRCA) is one of the most common cytopenic complications in T-LGL leukemia, with a reported incidence of 7.3–68.2% [4]. The treatment of secondary acquired PRCA typically relies on immunosuppressive therapy [5]. First-line therapeutic options include cyclosporine A (CsA), cyclophosphamide, and methotrexate, with or without glucocorticoids [[6], [7], [8], [9], [10], [11]]. However nearly half of patients exhibit primary refractoriness. However, there is currently no established standard of care for refractory T-LGL-associated PRCA, and effective salvage treatment options remain limited [5]. In recent years, epigenetic alterations have also been implicated in the pathogenesis of T-LGL leukemia; however, clinical evidence supporting epigenetic-targeted therapeutic strategies remains limited. Now, we here reported a case of refractory T-LGL leukemia complicated by PRCA, which was resistant to CsA and had been rapidly controlled with chidamide and thalidomide at early stage, and achieved long-term remission for six years under the maintenance treatment with chidamide alone. Case description A 47-year-old woman was admitted to our hospital on November 10, 2018 with progressive anemia. The patient presented with complaints of fatigue, palpitations, and dizziness. On physical examination, the patient appeared pale, suggestive of anemia. Cardiovascular and respiratory examinations were unremarkable. Abdominal examination revealed no significant abnormalities. Laboratory findings revealed white blood cells 7.71 × 109/L (normal reference range, 3.5–9.5 × 109/L) and lymphocytes 5.47 × 109/L (normal reference range, 1.1–3.2 × 109/L), red blood cell 1.02 × 1012/L (normal reference range, 3.8–5.1 × 1012/L), reticulocytes 0.0038 × 1012/L (normal reference range, 0.024–0.084 × 1012/L), hemoglobin 37 g/L (normal reference range, 115–150 g/L), and platelets 590 × 109/L (normal reference range, 100–300 × 109/L). Bone marrow aspirate smear showed granulocytic series accounting for 65%, whereas the erythroid series accounted for only 2%, all erythroid maturation stages other than pronormoblasts were observable, mature lymphocytes constituted 31% (detailed in Table 1). Bone marrow flow cytometry revealed a phenotype of CD5+, CD2+, CD3+, CD7-, CD8+, CD11c+, CD38+, CD57+, with a clonal T-cell receptor (TCR) variable β-chain (Vβ) 3 (detailed in Fig. 1). No Signal Transducer and Activator of Transcription 3 (STAT3) gene mutation was detected by reverse transcription-polymerase chain reaction. Based on the above clinical presentation, physical examination, and laboratory findings, the patient was diagnosed with T-LGL leukemia complicated by PRCA. Table 1Complete blood count, erythropoiesis assessment and bone marrow aspirate smear cytological examination of the patient at the diagnosis of T-LGLL and PRCA.CategoryParameterValueReference normal rangeComplete blood countHemoglobin37 (L)115–150 (g/L)Reticulocytes0.0038 (L)0.024–0.084 (10×10^12)Red blood cell1.02 (L)3.8–5.1 (10×10^12)Platelets590 (H)100–300 (10×10^9)White blood cells7.713.5–9.5 (10×10^9)Lymphocytes5.47 (H)1.1–3.2 (10×10^9)Erythropoiesis assessmentSerum erythropoietin340.62(H)2.59–18.5 (mIU/mL)Serum ferritin12513–150 (ng/mL)Bone marrow aspirate smear cytological examination (200 nucleated cells)Blast cells00–0.7 (%)Myeloblast0.50–1.8 (%)Promyelocyte10.4–3.9 (%)Neutrophilic myelocyte52.2–12.2 (%)Neutrophilic metamyelocyte19 (H)3.5–13.2 (%)Neutrophilic stab2016.4–32.1 (%)Neutrophilic segmented granulocyte12.54.2–21.2 (%)Eosinophilic metamyelocyte2 (H)0–1.8 (%)Eosinophilic band cell20.2–3.9 (%)Eosinophilic segmented granulocyte30–4.2 (%)Pronormoblast00–1.9 (%)Basophilic normoblast0.50.2–2.6 (%)Polychromatophilic normoblast0.5 (L)2.6–10.7 (%)Orthochromatic normoblast1 (L)5.2–17.5 (%)Mature lymphocyte3110.7–33.1 (%)Mature monocyte11–6.2 (%)Mature plasma cell11–6.2 (%)Granulocytes: Nucleated erythrocytes32.5:1(H)2–6:1 (%)Note: Marking values outside the reference ranges as high (H, red) or low (L, blue). Complete blood count, erythropoiesis assessment and bone marrow aspirate smear cytological examination of the patient at the diagnosis of T-LGLL and PRCA. Note: Marking values outside the reference ranges as high (H, red) or low (L, blue). Bone marrow flow cytometry at diagnosis. Given that CsA is a first-line agent for both T-LGL leukemia and PRCA, oral CsA was initiated following diagnosis on November 10, 2018, at a dose of 125 mg twice daily. However, after one month, hemoglobin remained as low as 48 g/L, necessitating two units of packed red blood cells per week for symptomatic anemia. The CsA trough and peak levels were measured at 126.0 μg/L and 1483.2 μg/L, respectively; the dose was subsequently reduced to 75 mg twice daily. After 3 months of CsA therapy, hemoglobin was only 56 g/L, with persistent and marked symptomatic anemia. The patient was diagnosed with Refractory T-LGL leukemia complicated by PRCA. Epigenetic modulation is another mechanism implicated in the pathogenesis of LGL leukemia [12]. Chidamide, as a histone deacetylase (HDAC) inhibitor, is approved for the treatment of relapsed or refractory peripheral T-cell lymphoma [13,14]. Given the epigenetic regulatory properties of chidamide, this patient provided informed consent and initiated treatment with chidamide (25 mg twice weekly) on January 24, 2019. Concurrently, thalidomide was administered adjunctively at 100 mg daily for its immunomodulatory effects. Notably, by Day 5 of therapy, hemoglobin rose from 49 g/L to 74 g/L, and the patient became transfusion-independent. By Day 28, hemoglobin reached 101 g/L and the patient’s fatigue, palpitations, and dizziness improved significantly. Then chidamide was reduced to 20 mg twice weekly. At six months, thalidomide was discontinued due to bilateral lower extremity edema without concurrent thrombosis. The lower-extremity edema resolved following discontinuation of thalidomide. Hemoglobin remained consistently above 110 g/L with chidamide-maintained clinical remission on serial following-up (detailed in Fig. 2). The persistent TCRvβ3 clone among LGLs accounted for 17.7%–45% of lymphocytes by flow cytometry (detailed in Table 2). During follow-up, the patient experienced intermittent leukopenia and the lowest white blood cell count was 1.91 × 109/L, which was managed with recombinant human granulocyte colony-stimulating factor (rhG-CSF) 75 μg daily for three to four days. Considering the leukopenia, chidamide was further reduced to 10 mg twice weekly. By December 30, 2021, the dose of chidamide had been further reduced to 10 mg once weekly. The patient has continued this regimen to date, with a sustained hematologic response and stable hemoglobin levels despite the substantial dose reduction. Changes in blood cell counts and hemoglobin levels. Table 2Monitoring of LGLs by flow cytometry during the treatment.Measurement of timeSpecimenDetailed expression of cluster of differentiationTCRvβ-clonalRate%2018/11/23Bone marrowCD5+, CD2+, CD3+, CD7-, CD8+, CD11c+, CD38+, CD57+TCRvβ315%2019/4/2Peripheral bloodCD5+, CD2+, CD3+, CD7-, CD8+, CD11c+, CD38+, CD57+Not evaluated34%2019/7/26Peripheral bloodCD5+, CD2+, CD3+, CD7-, CD8+, CD11c+, CD38-, CD57+TCRvβ317.7%2020/1/25Peripheral bloodCD5+, CD2+, CD3+, CD7-, CD8+, CD11c+, CD38+, CD57+Not evaluated45%2021/3/19Peripheral bloodCD5+, CD2+, CD3+, CD7-, CD8+, CD11c+, CD38+, CD57+TCRvβ332.9%2022/5/24Peripheral bloodCD5+, CD2+, CD3+, CD7+, CD8+, CD11c+, CD38+, CD57+TCRvβ342%Note: TCRvβ T-cell receptor (TCR) variable β-chain (Vβ). Monitoring of LGLs by flow cytometry during the treatment. Note: TCRvβ T-cell receptor (TCR) variable β-chain (Vβ). During long-term follow-up, no clinically significant hepatic or renal dysfunction, gastrointestinal intolerance, or infectious complications attributable to chidamide were observed. The fatigue present at initial presentation, which was considered related to anemia, improved substantially following treatment, and no new or worsening fatigue attributable to chidamide was noted. Apart from leukopenia requiring rhG-CSF support, no other clinically significant chidamide-related adverse events were observed. Until now, the patient has been followed for over 6 years and remains in chidamide-maintained clinical remission without any adverse reactions. Discussion Acquired PRCA is frequently an immunologically mediated disease, and treatment involves immunosuppressants. This case is notable in that the patient, diagnosed with T-LGL leukemia complicated by PRCA, exhibited anemia refractory to CsA but achieved rapid disease control with chidamide plus thalidomide in the early phase. Following thalidomide discontinuation due to bilateral lower extremity edema, the patient maintained long-term remission on chidamide monotherapy for over six years. The pathophysiological mechanism of LGL leukemia associated PRCA is likely via LGL mediated killing of erythroid colony units and burst forming units, thereby inhibiting the progression of erythroid precursor progression to mature erythrocytes [15]. Refractory T-LGL leukemia complicated by PRCA lacks a standardized salvage regimen. In recent years, epigenetic modifications have been shown to orchestrate core signaling cascades in T-LGL leukemia. Chidamide, in particular, has been demonstrated to play a critical role in regulating T-cell differentiation and function [16]. In our case, chidamide combined with thalidomide was administered to this patient who resistant to CsA at early stage, and transfusion independence was achieved within 5 days. The favorable outcome is ascribed to epigenetic modulation by chidamide combined with adjunctive immunoregulatory effects of thalidomide. Moreover, the sustained remission over the six-year follow-up may be attributed to the long-term regulatory effects of single-agent chidamide on TCR Vβ 3 clonal function after thalidomide discontinuation. Notably, belinostat, another HDAC inhibitor, has been reported to yield durable clinical and biologic responses in relapsed/refractory T-LGL leukemia [17]. Collectively, these findings suggest that HDAC inhibitors may serve as a viable therapeutic option for refractory T-LGL leukemia, although the precise underlying mechanisms warrant further investigation. Previously, chidamide also helped two patients with refractory T-LGL leukemia achieve early transfusion independence; however, one discontinued treatment owing to pulmonary infection and the other owing to diarrhea after six months [18]. In contrast, thalidomide was administered adjunctively in the early phase of our case for its anti-inflammatory and immunomodulatory effects. This patient rapidly achieved transfusion independence, and subsequent thalidomide discontinuation had no adverse impact on remission. Thalidomide is thought to exert its effects by potentiating T-cell function and has been used in the treatment of T-LGL leukemia in clinical practice [[19], [20], [21]]. For instance, a thalidomide-based regimen demonstrated promising efficacy in patients with LGL leukemia, with 75.0% achieving complete response and 15.4% achieving partial response [21]. Thus, thalidomide exerts a subsidiary effect on disease control at the early stage. Thus, thalidomide appears to play an adjunctive role in disease control of T-LGL leukemia during the early phase. Notably, an important consideration in this case is the balance between the hematologic efficacy and toxicity of chidamide. The development of leukopenia requiring rhG-CSF support suggests that hematologic toxicity may limit prolonged treatment, even at a reduced dose. Importantly, dose reduction was not accompanied by an apparent decline in hemoglobin, suggesting that the hematologic response may be maintained at lower drug exposure. The chidamide dose was progressively reduced from the initial regimen of 25 mg twice weekly to 10 mg once weekly, which is the patient’s current maintenance dose. Among refractory T-LGL-associated PRCA, the pharmacodynamic effect required for improvement of anemia may be achieved at substantially lower chidamide exposure than that used in conventional oncologic regimens. However, this hypothesis remains speculative and requires validation in additional patients and prospective dose-finding studies. T-LGL leukemia is characterized by chronic lymphoproliferation of cytotoxic T lymphocytes (CTLs) and is frequently associated with lineage-restricted cytopenias, and Vβ expansions can serve as surrogate markers of CTL clonality to assess clonal kinetics in T-LGL leukemia by flow cytometry, approximately 54% of patients with T-LGL leukemia maintain a consistent monoclonal TCR expansion [22]. Notably, in our case, the TCR Vβ3 clone persisted throughout serial flow cytometric monitoring, yet the patient achieved and maintained clinical remission on long-term chidamide monotherapy. We hypothesize that chidamide suppresses TCRvβ3 clonal activity and attenuates the destruction of erythroid precursors, thereby enabling sustained disease remission. In conclusion, we here reported a case of refractory T-LGL leukemia complicated by PRCA in which anemia was resistant to cyclosporine (Cyclosporine capsules), and had been rapidly controlled with chidamide and thalidomide at early stage, and this patient still achieved long-term remission under the maintenance treatment with chidamide alone for six years. Moreover, the TCRvβ3-clonal persistent by flow cytometry during the treatment. Thus, chidamide, one of the epigenetic regulating agents, offers a more convenient novel option for those patients with refractory T-LGL leukemia and PRCA, and further prospective studies are needed to elucidate the relevant mechanisms in the future. Ethics approval and consent to participate: The patients consented to receive the administration of chidamide and reporting of this case. The study was performed in accordance with the Declaration of Helsinki. Declaration of patient consent Patient consent is not required as patient identity is not disclosed or compromised. Availability of data and materials: All the data and materials were available. Funding: No funder. Declaration of generative AI use: None. CRediT authorship contribution statement Huan Tao: Writing – review & editing, Writing – original draft, Visualization, Methodology, Data curation. Nenggang Jiang: Writing – review & editing, Validation, Supervision, Software, Funding acquisition. Yongqian Jia: Writing – review & editing, Resources, Project administration, Investigation, Conceptualization. Declaration of competing interest The authors declare that they have no competing interests. Acknowledgements None. Contributor Information Huan Tao, Email: 1483941395@qq.com. Yongqian Jia, Email: jia_yq@scu.edu.cn. References